Indian Vaccine maker Bharat Biotech's intranasal vaccine for Covid-19, the first in the world, is scheduled to be introduced in the country as a booster dose shortly. The vaccine, iNCOVACC (BBV154), is now available on CoWin, and priced at Rs 800 for private markets and Rs 325 for supplies to the Centre and state governments, the Hyderabad-based company said.

Recently, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein.

This intranasal vaccine candidate was evaluated in phases I, II III clinical trials with successful results, the company said. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, it added.

Indian Vaccine maker Bharat Biotech's intranasal vaccine for Covid-19, the first in the world, is scheduled to be introduced in the country as a booster dose shortly. The vaccine, iNCOVACC (BBV154), is now available on CoWin, and priced at Rs 800 for private markets and Rs 325 for supplies to the Centre and state governments, the Hyderabad-based company said.

Recently, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein.

This intranasal vaccine candidate was evaluated in phases I, II III clinical trials with successful results, the company said. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, it added.